Anavex Life Sciences Corp (AVXL)

[Investor2014]

Reading the 10Q figures really rather impressive and actually frugal if you ask me.

The company has no debt, have managed to retain the cash balance through the use of LPC and continue to have two years runway including running all 3 announced trials with the help of outside grants.

If and when Anavex succeed in their first controlled trial showing indisputable efficacy, Missling should be applauded for having achieved that without sacrificing half the shop. Should eventually console money time-value troubles, perhaps.

Pretty much all other Biotechs I have come across have been out to the market with secondaries multiple times, yes and through promises and delays, often also licensing out portions of their future earnings for a measly upfront handout.

During the three months ended December 31, 2017, the Company issued to Lincoln Park an aggregate of 1,091,175 (2016: 4,500,012) shares of common stock under the Purchase Agreement, including 1,083,580 (2016: 4,472,841) shares of common stock for an aggregate purchase price of $4,228,520 (2016: $15,128,272) and 7,595 (2016: 27,171) commitment shares. At December 31, 2017, an amount of $17,143,007 remained available under the 2015 Purchase Agreement.